These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27039224)

  • 21. Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis.
    Bader RM; Jonas MM; Mitchell PD; Wiggins S; Lee CK
    J Cyst Fibros; 2019 Mar; 18(2):280-285. PubMed ID: 30509601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
    Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
    Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
    Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
    Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography.
    Ratchatasettakul K; Rattanasiri S; Promson K; Sringam P; Sobhonslidsuk A
    BMC Gastroenterol; 2017 Apr; 17(1):50. PubMed ID: 28407734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.
    Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Dal Bello B; Filice G; Filice C
    World J Gastroenterol; 2014 Jun; 20(21):6626-31. PubMed ID: 24914387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Pu K; Wang Y; Bai S; Wei H; Zhou Y; Fan J; Qiao L
    BMC Gastroenterol; 2019 Apr; 19(1):51. PubMed ID: 30961539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.
    Caussy C; Alquiraish MH; Nguyen P; Hernandez C; Cepin S; Fortney LE; Ajmera V; Bettencourt R; Collier S; Hooker J; Sy E; Rizo E; Richards L; Sirlin CB; Loomba R
    Hepatology; 2018 Apr; 67(4):1348-1359. PubMed ID: 29108123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quick assessment with controlled attenuation parameter for hepatic steatosis in children based on MRI-PDFF as the gold standard.
    Shin J; Kim MJ; Shin HJ; Yoon H; Kim S; Koh H; Lee MJ
    BMC Pediatr; 2019 Apr; 19(1):112. PubMed ID: 30987634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients: A biopsy-controlled study.
    Darweesh SK; Omar H; Medhat E; Abd-Al Aziz RA; Ayman H; Saad Y; Yosry A
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1010-1016. PubMed ID: 30807444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.
    Xu L; Lu W; Li P; Shen F; Mi YQ; Fan JG
    Dig Liver Dis; 2017 Aug; 49(8):910-917. PubMed ID: 28433586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method.
    Bende F; Sporea I; Șirli R; Bâldea V; Lazăr A; Lupușoru R; Fofiu R; Popescu A
    Med Ultrason; 2021 Feb; 23(1):7-14. PubMed ID: 33220028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
    Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
    J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of controlled attenuation parameter compared with ultrasound for detecting hepatic steatosis in children with severe obesity.
    Runge JH; van Giessen J; Draijer LG; Deurloo EE; Smets AMJB; Benninga MA; Koot BGP; Stoker J
    Eur Radiol; 2021 Mar; 31(3):1588-1596. PubMed ID: 32910234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography.
    Yilmaz Y; Ergelen R; Akin H; Imeryuz N
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1330-4. PubMed ID: 23660937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees.
    Kim JK; Lee KS; Choi JR; Chung HJ; Jung DH; Lee KA; Lee JI
    Gut Liver; 2015 May; 9(3):405-10. PubMed ID: 25717046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validating controlled attenuation parameter in the assessment of hepatic steatosis in living liver donors.
    Broering D; Shawkat M; Albenmousa A; Abaalkhail F; Alabbad S; Al-Hamoudi W; Alghamdi S; Alqahthani S; Jaafari A; Troisi R; Bzeizi K
    PLoS One; 2021; 16(5):e0251487. PubMed ID: 33984017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled attenuation parameter in the diagnosis of different liver steatosis groups in children with obesity.
    Yang L; Lin Y; Zhu YF; Zhu YY; Liang ZM; Wu GS
    Pediatr Obes; 2022 Jun; 17(6):e12893. PubMed ID: 35092183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.
    Macías J; Real LM; Rivero-Juárez A; Merchante N; Camacho A; Neukam K; Rivero A; Mancebo M; Pineda JA
    HIV Med; 2016 Nov; 17(10):766-773. PubMed ID: 27028546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease.
    Kuroda H; Abe T; Fujiwara Y; Nagasawa T; Takikawa Y
    J Med Ultrason (2001); 2021 Oct; 48(4):471-480. PubMed ID: 34415481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver].
    Shen F; Zheng R; Mi Y; Shi J; Chen G; Chen J; Xu L; Pan Q; Xu L; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Dec; 22(12):926-31. PubMed ID: 25654287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.